Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others.
Boehringer Ingelheim Pharma GmbH & Co. KG and Immunitas Therapeutics Inc. have signed a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases.
AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.
